Cns Pharmaceuticals Inc Quick Ratio (CNSP) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Cns Pharmaceuticals Inc   (NASDAQ: CNSP)

Cns Pharmaceuticals Inc 's Quick Ratio

CNSP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Cns Pharmaceuticals Inc 's Cash & cash equivalent grew by 577.26 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Cns Pharmaceuticals Inc 's Quick Ratio to 5.35, above Cns Pharmaceuticals Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 178 other companies have achieved higher Quick Ratio than Cns Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 773, from total ranking in the first quarter 2026 at 1958.

Explain Quick Ratio?
How much Cash & cash equivalents CNSP´s has?
What are CNSP´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CNSP Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 170.3 % 64.89 % 62.46 % -51.71 % -79.55 %
Y / Y Cash & cash equivalent Change 64.76 % -77.38 % 11.45 % 41.46 % 713.23 %
Quick Ratio MRQ 5.35 0.64 1.76 5.03 8.77
CNSP's Total Ranking # 773 # 1958 # 1231 # 514 # 301
Seq. Current Liabilities Change -18.43 % 11.74 % 109.32 % 41.67 % -50.24 %
Seq. Cash & cash equivalent Change 577.26 % -59.02 % -27 % -18.68 % -7.03 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 179
Healthcare Sector # 290
Overall Market # 773


Quick Ratio Statistics
High Average Low
18.81 4.18 0.09
(Mar 31 2020)   (Dec 31 2023)




Financial Statements
Cns Pharmaceuticals Inc 's Current Liabilities $ 4 Millions Visit CNSP's Balance sheet
Cns Pharmaceuticals Inc 's Cash & cash equivalent $ 20 Millions Visit CNSP's Balance sheet
Source of CNSP's Sales Visit CNSP's Sales by Geography


Cumulative Cns Pharmaceuticals Inc 's Quick Ratio

CNSP's Quick Ratio for the trailling 12 Months

CNSP Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 33.86 % -25.42 % -47.41 % -62.48 % -53.4 %
Y / Y Cash & cash equivalent TTM Growth 3.6 % 14.91 % 168.36 % 322.27 % 925.54 %
Quick Ratio TTM 2.78 2.67 4.13 4.8 3.59
Total Ranking TTM # 3738 # 3804 # 2822 # 2710 # 2643
Seq. Current Liabilities TTM Growth 19.58 % 17.64 % 18.24 % -19.53 % -33.37 %
Seq. Cash & cash equivalent TTM Growth 24.44 % -23.9 % 1.78 % 7.49 % 38.03 %

Quick ratio ranking by company, industry and sector >> Back to CNSP Financial Strength Comparisons >> Go to Compare CNSP Quick Ratio to its Competitors

On the trailing twelve months basis CNSP Cash & cash equivalent soared by 64.76 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Cns Pharmaceuticals Inc 's Quick Ratio to 2.78, Quick Ratio remained below CNSP average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 428 other companies have achieved higher Quick Ratio than Cns Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 3738, from total ranking during the twelve months ending first quarter 2026 at 3804.

Explain Quick Ratio?
How much Cash & cash equivalents CNSP´s has?
What are CNSP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 429
Healthcare Sector # 873
Within the Market # 3738


trailing twelve months Quick Ratio Statistics
High Average Low
7.75 3.28 0.16
(Dec 31 2020)   (Jun 30 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Alto Neuroscience Inc   14.64 $ 243.733  Millions$ 16.652  Millions
Tenax Therapeutics Inc   14.62 $ 118.000  Millions$ 8.073  Millions
Jade Biosciences Inc   14.61 $ 461.205  Millions$ 31.570  Millions
Immunome Inc   14.56 $ 519.996  Millions$ 35.713  Millions
Sensei Biotherapeutics Inc   14.54 $ 186.441  Millions$ 12.824  Millions
Cytokinetics Incorporated  14.39 $ 2,610.415  Millions$ 181.429  Millions
Canton Strategic Holdings Inc   14.18 $ 37.242  Millions$ 2.626  Millions
An2 Therapeutics Inc   14.04 $ 78.387  Millions$ 5.585  Millions
Aclaris Therapeutics Inc   13.97 $ 394.443  Millions$ 28.241  Millions
Pmv Pharmaceuticals Inc   13.85 $ 146.393  Millions$ 10.568  Millions
Generate Biomedicines Inc   13.76 $ 779.456  Millions$ 56.636  Millions
First Tracks Biotherapeutics Inc   13.50 $ 168.018  Millions$ 12.447  Millions
Arrivent Biopharma inc   13.41 $ 373.401  Millions$ 27.844  Millions
Cogent Biosciences Inc   13.36 $ 792.300  Millions$ 59.296  Millions
Aprea Therapeutics Inc   13.33 $ 41.233  Millions$ 3.092  Millions
Polaryx Therapeutics Inc   13.22 $ 11.542  Millions$ 0.873  Millions
Monopar Therapeutics Inc   13.14 $ 52.758  Millions$ 4.016  Millions
Lexicon Pharmaceuticals Inc   12.96 $ 190.610  Millions$ 14.706  Millions
Korro Bio Inc   12.89 $ 162.805  Millions$ 12.628  Millions
Atea Pharmaceuticals Inc   12.89 $ 362.382  Millions$ 28.124  Millions
Oric Pharmaceuticals Inc   12.76 $ 264.761  Millions$ 20.756  Millions
Diamedica Therapeutics Inc   12.42 $ 81.875  Millions$ 6.594  Millions
Vtv Therapeutics Inc   12.35 $ 86.643  Millions$ 7.017  Millions
Theravance Biopharma inc   12.30 $ 378.546  Millions$ 30.766  Millions
Coya Therapeutics Inc   12.29 $ 43.181  Millions$ 3.512  Millions
Bridgebio Oncology Therapeutics Inc   12.28 $ 634.167  Millions$ 51.634  Millions
Ocular Therapeutix Inc   12.17 $ 598.641  Millions$ 49.174  Millions
Wave Life Sciences Ltd   12.07 $ 613.194  Millions$ 50.815  Millions
Amylyx Pharmaceuticals Inc   11.86 $ 250.760  Millions$ 21.150  Millions
Moonlake Immunotherapeutics  11.83 $ 537.000  Millions$ 45.392  Millions

Date modified: 2026-09-03T23:39:15+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.